Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Monoclonal Antibodies Alzheimer's Disease Combination Therapy Eli Lilly Oncology Novo Nordisk Immunotherapy GLP-1 Drugs

AstraZeneca Halts Phase III Lung Cancer Trial of Volrustomig

An independent committee found the drug was unlikely to improve progression‑free or overall survival in the trial’s PD‑L1 <1% analysis group.

Stories older than 24h

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

Pfizer Raises 2026 Revenue Floor After Q2 Beat as Covid Sales Fall

AstraZeneca and Bristol Myers Squibb Held Talks on $400 Billion Merger

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

FDA Advisers Find Replimune’s RP1 Trial Results Clinically Meaningful

UK Clears Aficamten (MYQORZO) for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Snake Blood Proteins Could Yield Far More Potent, Broader Antivenoms

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

Anvisa Says Retatrutida Is Unapproved as Illegal Versions Spread

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC